Osimertinib, a third-generation EGFR TKI, is the standard therapy for previously untreated
EGFR-mutated non-small cell lung cancer patients following the landmark FLAURA study …

The clinical efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-
TKIs) is limited by the emergence of drug resistance. We hypothesise that restoring …

Background This multicenter phase 2 trial evaluated the safety and efficacy of osimertinib
and platinum-based chemotherapy (OPP) in patients with previously untreated EGFR …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC …

In European countries, nearly 10% of all hospital admissions are related to respiratory
diseases, mainly chronic life-threatening diseases such as COPD, pulmonary hypertension …

The therapies targeting mutations of driver genes in cancer have advanced into clinical trials
for a variety of tumors. In glioblastoma (GBM), epidermal growth factor receptor (EGFR) is …

Although anti-angiogenic agents have been of limited use in the treatment of non-small cell
lung cancer (NSCLC) until recently, further roles for the use of angiogenesis inhibition have …

Hexahydroquinoline (HHQ) scaffold was constructed and recruited for development of new
series of anticancer agents. Thirty-two new compounds were synthesised where x-ray …

Epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC) is an
important subtype of lung cancer. With the existing and ongoing research and multiple …

Simple Summary Patients with lung cancer benefit from more effective treatments, such as
targeted therapies, and the overall survival has increased in the past decade. However, the …